公开(公告)号：EP3093023A4

公开(公告)日：2017-10-11

申请号：EP15740157

申请日：2015-01-23

申请人： QUARRYMEN & CO INC

发明人： UEDA MINORU

IPC分类号： A61K35/32 ,  A61K38/18 ,  A61K38/19 ,  A61K38/30 ,  A61P35/00

CPC分类号： A61K38/30 ,  A61K35/12 ,  A61K35/32 ,  A61K38/1841 ,  A61K38/1866 ,  A61K38/195 ,  C12N5/0664 ,  C12N5/0696 ,  C12N2500/02 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2501/105 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/21 ,  C12N2501/60 ,  C12N2501/998 ,  C12N2506/1361 ,  C12N2510/04

摘要： The purpose of the present invention is to provide a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27°C under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.